5 minThe US FDA has recently granted approval to AstraZeneca’s Baxfendy (baxdrostat). As a global first-in-class, potent, and selective aldosterone synthase inhibitor (ASI), Baxfendy is indicated for use in combination with other antihypertensive agents to lower blood pressure in adults whose hypertension is not adequately controlled by conventional therapies.
In the field of hypertension management, while classic agents such as ACE inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs) have formed a solid therapeutic foundation, the clinical needs for uncontrolled and resistant hypertension remain largely unmet. Out of 1.4 billion hypertension patients globally, approximately half fail to reach target blood pressure levels even when using multiple drug combinations.
Target Mechanism: Conquering the "High Selectivity" Holy Grail of CYP11B2
Aldosterone is the central hormone regulating water-sodium balance and blood pressure. Pathologically elevated aldosterone levels lead to sodium retention and reduced vascular compliance, directly mediating target organ damage in the cardiorenal system. Consequently, inhibiting aldosterone synthesis at its source has long been a highly attractive target in cardiovascular drug development.
However, the challenge lies in the high degree of homology: aldosterone synthase (encoded by the CYP11B2gene) and 11$\beta$-hydroxylase (encoded by the CYP11B1 gene, responsible for cortisol synthesis) share 93% sequence homology. The historical R&D bottleneck has been achieving aldosterone inhibition without "off-target" suppression of cortisol synthesis, thereby avoiding severe adverse effects such as adrenal insufficiency.
Baxfendy resolves this pharmacological deadlock through a novel small-molecule structure:
-
Superior Selectivity: Preclinical and clinical studies demonstrate that Baxfendy significantly lowers plasma aldosterone levels across a wide dose range without impacting cortisol levels.
-
Upstream Blockade: Unlike existing Mineralocorticoid Receptor Antagonists (MRAs, e.g., spironolactone or eplerenone), Baxfendy directly inhibits CYP11B2 to block aldosterone production. This avoids the compensatory "aldosterone escape" (rebound in hormone levels) often seen with receptor-level blockade.
Clinical Data: Robust Efficacy in the BaxHTN Phase III Trial
The FDA approval was primarily based on the positive results of the pivotal Phase III BaxHTN trial. Published in The New England Journal of Medicine (NEJM), the study evaluated the efficacy and safety of Baxfendy as an add-on to standard-of-care (SoC) regimens (2–3 medications, including at least one diuretic).
In the 12-week, randomized, double-blind, placebo-controlled phase (n=796), Baxfendy demonstrated dose-dependent and clinically significant reductions in mean seated systolic blood pressure (SBP):
-
Baxfendy 2mg: Achieved a 15.7 mmHg absolute reduction from baseline (9.8 mmHg placebo-adjusted; $p < 0.001$).
-
Baxfendy 1mg: Achieved a 14.5 mmHg absolute reduction from baseline (8.7 mmHg placebo-adjusted; $p < 0.001$).
Clinical and Epidemiological Implications
The study showed consistent antihypertensive efficacy across both uncontrolled and treatment-resistant subgroups. Epidemiological data indicates that every 10 mmHg decrease in SBP is associated with an approximately 20% lower risk of Major Adverse Cardiovascular Events (MACE). The nearly double-digit placebo-adjusted reduction achieved by Baxfendy is expected to translate into significant long-term cardiorenal benefits.
Furthermore, the Bax24 Phase III trial, published in The Lancet, confirmed that Baxfendy significantly lowers 24-hour ambulatory SBP in patients with resistant hypertension, effectively controlling the "morning surge" that is closely linked to early-morning cardiovascular events.
Safety Evaluation and Tolerability
Baxfendy demonstrated a favorable safety window throughout the BaxHTN program:
-
No unanticipated safety signals were identified.
-
Favorable tolerability was maintained throughout the 52-week long-term safety extension.
-
The study design included a randomized withdrawal period (Weeks 24–32), which effectively demonstrated the durability of the treatment effect and a low rate of rebound.
A Core Asset in AstraZeneca’s CVRM Matrix
AstraZeneca acquired CinCor Pharma in February 2023 for approximately $1.3 billion, with the primary objective of securing Baxfendy (baxdrostat). This approval not only fills an innovation gap in the hypertension market but also fits perfectly within AstraZeneca’s comprehensive Cardiovascular, Renal, and Metabolism (CVRM) ecosystem.
According to AstraZeneca’s disclosures, the clinical potential of Baxfendy is being expanded horizontally:
-
Cardiorenal Combination Therapy: Clinical trials are currently evaluating Baxfendy in combination with the SGLT2 inhibitor Dapagliflozin for chronic kidney disease (CKD) with hypertension. The complementary mechanisms—hemodynamic regulation (ASI) and metabolic remodeling (SGLT2i)—aim to establish a new frontier in cardiorenal protection.
-
Indication Expansion: Investigations are underway for Baxfendy as a monotherapy for Primary Aldosteronism and for the prevention of heart failure progression in hypertensive patients.
